Having identified RANKL as a secreted factor that increases MITF expression, combined with evidence that RANKL signalling is linked to survival of patients in other cancers (de Groot, Appelman‐Dijkstra, van der Burg, & Kroep, 2018), we next wanted to assess the role of RANKL in mediating resistance to BRAF inhibition. Here, MITF is linked to cancer.